Amgen Inc. (NASDAQ:AMGN – Get Free Report) was the target of unusually large options trading on Thursday. Investors purchased 38,050 put options on the stock. This is an increase of 309% compared to the typical volume of 9,295 put options.
Wall Street Analysts Forecast Growth
AMGN has been the subject of a number of recent analyst reports. Morgan Stanley reissued an “overweight” rating and set a $362.00 target price on shares of Amgen in a research report on Wednesday, August 19th. Argus increased their price objective on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. HSBC downgraded shares of Amgen from a “buy” rating to a “hold” rating and lowered their target price for the stock from $445.00 to $425.00 in a research note on Thursday. Guggenheim boosted their target price on shares of Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a report on Monday, August 10th. Finally, Sanford C. Bernstein increased their price target on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $381.68.
Read Our Latest Stock Analysis on AMGN
Amgen Stock Performance
Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the prior year, the firm earned $6.02 earnings per share. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen will post 22.97 EPS for the current year.
Amgen Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.
Key Stories Impacting Amgen
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Amgen and AstraZeneca reported that the Imdelltra-Imfinzi combination improved survival outcomes in a late-stage study of first-line extensive-stage small-cell lung cancer. The results could expand the commercial opportunity for both medicines. AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
- Positive Sentiment: Amgen announced a Phase 4 trial evaluating Repatha’s effect on coronary plaque, potentially generating additional evidence to support the cholesterol drug’s use and market position. Amgen’s New Repatha Plaque Trial: What Investors Should Watch
- Positive Sentiment: TD Cowen and Piper Sandler maintained Buy ratings, while a separate analysis argued that the recent Novartis-related selloff created an attractive entry point. TD Cowen Keeps Their Buy Rating on Amgen
- Neutral Sentiment: Amgen presented at the Wells Fargo healthcare conference and is scheduled to present at the Morgan Stanley healthcare conference, giving management opportunities to address pipeline progress and the outlook for Repatha and MariTide. Amgen to Present at the Morgan Stanley Healthcare Conference
- Neutral Sentiment: Cantor Fitzgerald reaffirmed a Neutral rating, while Wells Fargo maintained Hold, reflecting mixed analyst views despite some bullish coverage. Cantor Fitzgerald Reaffirms Neutral Rating for Amgen
- Negative Sentiment: Novartis reported a failure in a trial involving an oral cholesterol treatment, increasing uncertainty around the cholesterol-drug class and contributing to a sharp decline in Amgen shares because of concerns about Repatha’s competitive and valuation outlook. Amgen Falls as Novartis Trial Failure Clouds Cholesterol Drug Class
- Negative Sentiment: Investors purchased an unusually large number of Amgen put options—more than three times typical volume—signaling heightened near-term hedging or bearish speculation.
- Negative Sentiment: Analysts noted that declining Prolia and XGEVA sales from biosimilar competition, combined with the cost of funding MariTide, could pressure margins and make Amgen’s valuation look less compelling. Amgen’s Forward Multiple Looks Cheap Until You Price the Margins It Assumes
Insider Activity
In other news, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 over the last ninety days. Company insiders own 0.85% of the company’s stock.
Institutional Trading of Amgen
A number of hedge funds and other institutional investors have recently bought and sold shares of AMGN. Tower View Wealth Management LLC lifted its position in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Evergreen Advisors LLC purchased a new stake in shares of Amgen in the first quarter valued at about $37,000. Sfam LLC bought a new position in shares of Amgen during the fourth quarter valued at about $38,000. Advocate Investing Services LLC purchased a new position in Amgen during the fourth quarter worth about $39,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in Amgen in the 4th quarter worth about $44,000. Institutional investors own 76.50% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.
Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.
Read More
- Five stocks we like better than Amgen
- IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
